Opus Genetics (IRD) Capital Expenditures (2010 - 2019)
Opus Genetics (IRD) posted quarterly Capital Expenditures of $5617.0 for Q4 2019, down 9.43% quarter-over-quarter from $6202.0 in Q2 2019.
Powered by 
Analysis
Opus Genetics (IRD) Capital Expenditures (2010 - 2019) Analysis & Trends
Opus Genetics (IRD) has reported Capital Expenditures for 9 consecutive years, with $5617.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Capital Expenditures changed N/A year-over-year to $5617.0; the TTM figure through Dec 2019 stood at $25000.0 (down 36.26% YoY), while the FY2019 annual figure was $25000.0, down 36.26% from the prior year.
- Capital Expenditures fell to $5617.0 in Q4 2019 per IRD's latest filing, from $6202.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $53799.0 in Q4 2017 and bottomed at $403.0 in Q4 2016.
- Historically, Capital Expenditures has averaged $11686.7 across 5 years, with a median of $5106.5 in 2016.
- Annual changes were most pronounced in 2016 — Capital Expenditures plunged 98.13% — and 2017, when it surged 13249.63%.
- Opus Genetics' Capital Expenditures stood at $9803.0 in 2015, then slumped by 95.89% to $403.0 in 2016, then soared by 13249.63% to $53799.0 in 2017, then slumped by 33.58% to $35731.0 in 2018, then sank by 84.28% to $5617.0 in 2019.
- Business Quant data shows IRD's Capital Expenditures at $5617.0 in Q4 2019, $6202.0 in Q2 2019, and $13181.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 5,617.00 |
| Jun 30, 2019 | 6,202.00 |
| Mar 31, 2019 | 13,181.00 |
| Sep 30, 2018 | 35,731.00 |
| Jun 30, 2018 | 973.00 |
| Mar 31, 2018 | 2,520.00 |
| Dec 31, 2017 | 53,799.00 |
| Sep 30, 2017 | 3,459.00 |
| Jun 30, 2017 | 13,945.00 |
| Mar 31, 2017 | 3,965.00 |
| Dec 31, 2016 | 403.00 |
| Sep 30, 2016 | 752.00 |
| Jun 30, 2016 | 2,915.00 |
| Mar 31, 2016 | 4,596.00 |
| Dec 31, 2015 | 9,803.00 |
| Sep 30, 2015 | 40,111.00 |
| Jun 30, 2015 | 4,453.00 |
| Mar 31, 2015 | 7,935.00 |
| Dec 31, 2014 | 11,095.00 |
| Sep 30, 2014 | 15,940.00 |